Lucila Garcia-Contreras

Contact Information:
Lucila Garcia-Contreras



 

Garcia-Contreras, Lucila (HSC)
Assistant Professor

Department of:

College Of Pharmacy/Pharmaceutical Sciences -Assistant Professor

Center of:

Education:

Dept. of Pharmaceutical and Biomedical Sciences, College of Pharmacy, Univ. of Georgia. Athens, GA   PhD   1999
Dept. of Pharmaceutics, College of Pharmacy, Univ. of Georgia. Athens, GA   Master of Science   1995

Professional Interest/Expertise/Specializations:
The main interest of our laboratory is the targeted delivery of drugs and primarily Pulmonary Drug Delivery. Our goal is to design therapies that are more efficient and more convenient in delivering therapeutic or prophylactic agents to the site of action, thereby maximizing efficacy and efficiency of the agent and minimizing its undesired side effects. My research objectives are encompassed in the following four areas: To study mechanisms of drug transport in the lung in order to maximize delivery strategies; To optimize currently proposed therapies for the treatment of pulmonary diseases such as tuberculosis and cystic fibrosis; To understand the mechanisms of immunogenicity and protection when vaccines are administered by the pulmonary route; and To design more effective therapies for the treatment of lung cancer.

Websites:

Research Projects:

Stable, Needleless Subunit Vaccine Against Shigella ssp (NIH NIAID)) R21
Inhaled Caprazamycin for Tuberculosis Therapy (NIAID/NIH through RTI International)
Inhaled SHetA2 Dry Power Aerosols as Novel Treatment for Tuberculosis (PHF Seed Grant)
An Inhaled Dry Powder Formulation for the Treatment Multi-Drug Resistant Tuberculosis (NIH/SBIR/NIAID)
Development of SHetA2 Vaginal Suppositories for Treatment of Cervical Dysplasia (UoTexas/MD Anderson CC)

Selected Publications:

Lung anatomy and physiology and their implications for pulmonary drug delivery
2014    Verma RK, Ibrahim M and Garcia-Contreras L
Chapter 1 of Pulmonary Drug Delivery: Advances and Challenges
Mechanisms of absorption and elimination of drugs administered by inhalation
2013    Ibrahim M and Garcia-Contreras L
Therapeutic Delivery, 4
Liquid Chromatographic Determination of CPZEN-45, a Novel Anti-tubercular Drug, in Biological Samples
2013    Hanif SNM, Hickey AJ, and Garcia Contreras L
Journal of Pharmaceutical and Biomedical Analysis
Pharmacokinetics of CPZEN-45, a Novel Anti-tuberculosis Drug in Mail Guinea Pigs
2013    Hanif SNM, Raghuvanshi D, Durham P, Hickey AJ, Garcia-Contreras L.
J Aerosol Med
Pharmacokinetics of CPZEN-45, a novel anti-tuberculosis drug, in male guinea pigs
2013    Hanif SNM, Durham D, Hickey AJ and Garcia-Contreras L
Journal of Antimicrobial Chemotherapy.
Development of an HPLC Method to Determine CPZEN-45 in Biological Matrices
2013    Hanif SNM, Hickey AJ, Garcia-Contreras L.
J Aerosol Med
Pharmaceutical Aerosols for the Treatment and Prevention of Tuberculosis
2012    Garica-Contreras L.
Front. Cell. Inf. Microbio
Formulation of a Dry Powder Nasal Vaccine against West Nile Virus
2012    Venter L, Johnson BT, Abraham SN, Staats HF, Garcai-Conteras L
Respiratory Drug Delivery
Formulation Strategies for a Nasal Dry Powder Vaccine with Insoluble Adjuvants
2012    Venter L, Johnson BT, Raghuvanshi D, Abraham SN, Staats HF, Garcai-Conteras L
Respiratory Drug Delivery
Isoxyl Assays in Plasma
2012    Garcia-Contreras L
J Pharmaceutical and Biomedical Analysis
Inhaled Vaccines for the Prevention of Tuberculosis
2012    Garcia-Contreras L, Awasthi S, Hanif SNM, Hickey AJ

Inhaled capreomycin large porous particles for the treatment of tuberculosis in the guinea pig model.
   Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, VerBerkmoes J, Germishuizen WA, Fourie PB, Hickey AJ, Edwards D.
Antimicrob Agents Ch 2007; 51(6): 2830-2836
Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant mycobacterium tuberculosis antigen 85B.
   Lu D, Garcia-Contreras L, Zu D, Kurtz SL, Liu J, Braunstein M, McMurray DN, Hickey AJ.
Pharmaceut Res 2007; 24(10): 1834-1843
Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres doses in the treatment of tuberculosis in the guinea pig.
   Garcia-Contreras L, Sethuraman V, Kazantseva M, Hickey AJ.
J Antimicrob Chemoth 2006; 58(9): 980-986
Implications of increased nanoparticle absorption by infant lungs: Future prospects
   Ibrahim M and Garcia-Contreras L
Therapeutic Delivery
In vivo Animal Models for Drug Delivery Across the Airway Mucosal Barrier.
   Cryan SA, Sivadas N, Garcia-Contreras L.
Adv Drug Deliver Rev 2007; 59(11): 1133-1151.
Evaluation of the pharmacokinetics of rifampicin encapsulated in porous nanoparticle-aggregate particles (Rif-PNAPs) for the treatment of tuberculosis.
   Padilla-Carlin DJ, Sung JC, Garcia-Contreras L, VerBerkmoes JL, Peloquin CA, Elbert K, Bloom BR, Hickey AJ, Edwards DA.
In: Dalby RN, Byron PR, Peart J, Suman JD, Farr S, Young PM, editors. Respiratory Drug Delivery 2008. Vol. 3. Davis Healthcare
Efficacy of inhaled rifampicin biodegradable microspheres in the treatment of pulmonary tuberculosis.
   Garcia-Contreras L, Hickey AJ.
In: Dalby RN, Byron PR, Peart J, Suman JD, Farr S, Young PM, editors. Respiratory Drug Delivery 2008. Vol. 3. Davis Healthcare International Publishing, LCC. River Grove, IL. 2008
Targeted delivery of capreomycin to the lungs for MDR-TB treatment.
   Fiegel J, Garcia-Contreras L, Elbert K, Hawi A, Thomas M, VerBerkmoes J, Germishuizen WA, Fourie PB, Hickey AJ, Edwards D.
Pharmaceut Res 2008; 25(4): 805-811
A novel aerosol vaccine against tuberculosis.
   Garcia-Contreras L, Wong Y-L, Muttil P, Padilla-Carlin DJ, DeRousse J, Goonesekera S, Elbert K, Bloom BR, Hickey AJ, Edwards DA.
In: Dalby RN, Byron PR, Peart J, Suman JD, Farr S, Young PM, editors. Respiratory Drug Delivery 2008. Vol. 3. Davis Healthcare International Publishing, LCC. River Grove, IL. 2008
Immunization by a bacterial aerosol.
   Garcia-Contreras L, Wong Y-L, Muttil P, Padilla D, Sadoff J, DeRousse J, Germishuizen WA, Goonesekera S, Elbert K, Bloom BR, Miller R, Fourie B, Hickey AJ, Edwards D.
Proceedings of the National Academy of Sciences, USA (PNAS) 2008; 105(12): 4656-4660
Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines.
   Wang C, Muttil P, Lu D, Beltran-Torres AA, Garcia-Contreras L, Hickey AJ.
AAPS Journal 2009; 11(1): 139-147
Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.
   Sung JC, Garcia-Contreras L, VerBerkmoes JL, Peloquin CA, Elbert K, Hickey AJ, Edwards D.
Antimicrobial Agents and Chemotherapy; 53(4): 1338-1343
Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery.
   SungJC, Padilla DJ, Garcia-Contreras L, VerBerkmoes JL, Durbin D, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DA.
Pharmaceutical Research; 26(8): 1847-1855
Pulmonary immunization using antigen 85-B polymeric micropatricles to prevent tubercolosis.
   Lu DL, Garcia-Contreras L, Muttil P, Padilla D, Xu D, Liu J, Braunstein M, McMurray DN, Hickey AJ.
The AAPS Journal; 12(3): 338-347
In vivo models for controlled release pulmonary drug delivery. In:
   Garcia-Contreras L.
HDC Smyth and AJ Hickey, editors.Controlled Release Science and Technology, Springer Science and Business Medica LLC. New York, NY
Dry powder PA-824 aerosols for the treatment of tuberculosis in guinea pigs.
   Garcia-Contreras L, Sung JC, Muttil P, Padilla D, Telko M, VerBerkmoes JL, Elbert KJ, Hickey AJ, Edwards DA.
Antimicro Agents Ch ; 54(4): 1436-1442.
Keywords, Tags: